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ABSTRACT
Objective: To extend the phenotypic description of Charcot-Marie-Tooth disease (CMTX1) and to
draw new genotype-phenotype relationships.
Methods: Mutations in GJB1 cause the main X-linked form of CMTX (CMTX1). We report cross-
sectional data from 160 patients (from 120 different families, with 89 different mutations) seen
at the Inherited Neuropathies Consortium centers.
Results: We evaluated 87 males who had a mean age of 41 years (range 10–78 years) and 73
females who had a mean age of 46 years (range 15–84 years). Sensory-motor polyneuropathy
affects both sexes, more severely in males than in females, and there was a strong correlation
between age and disease burden in males but not in females. Compared with females, males had
more severe reduction in motor and sensory neurophysiology parameters. In contrast to females,
the radial nerve sensory response in older males tended to be more severely affected compared
with younger males. Median and ulnar nerve motor amplitudes were also more severely affected
in older males, whereas ulnar nerve motor potentials tended to be more affected in older females.
Conversely, there were no statistical differences between the sexes in other features of the
disease, such as problems with balance and hand dexterity.
Conclusions: In the absence of a phenotypic correlation with specific GJB1 mutations, sex-
specific distinctions and clinically relevant attributes need to be incorporated into the measure-
ments for clinical trials in people with CMTX1.
ClinicalTrials.gov identifier: NCT01193075. Neurology® 2017;89:927–935
GLOSSARY
ANCOVA 5 analysis of covariance; CMAP 5 compound muscle action potential; CMT 5 Charcot-Marie-Tooth disease;
CMTES 5 Charcot-Marie-Tooth disease examination score; CMTNS 5 Charcot-Marie-Tooth disease neuropathy score;
CMTX1 5 X-linked form of Charcot-Marie-Tooth disease; Cx32 5 connexin32; INC 5 Inherited Neuropathies Consortium;
NCV 5 nerve conduction velocity; SNAP 5 sensory nerve action potential.
Charcot-Marie-Tooth disease (CMT) is a group of inherited neuropathies characterized by
a nonsyndromic, chronic, motor, and sensory polyneuropathy. CMTX1 is X-linked; it is the
second most common subtype, after CMT1A,1 and is caused by mutations in the GJB1.2
GJB1 encodes connexin32 (Cx32), an intrinsic membrane protein of the gap junction gene
family.3 The function of Cx32 that may be relevant to neuropathy is that it forms gap junctions
between the layers of the Schwann cell myelin sheath.4
Over 400 GJB1 mutations have been identified, affecting all domains of the Cx32 protein
(figure 1) (hihg.med.miami.edu/code/http/cmt/public_html/index.html#/). The majority are
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missense mutations, but other mutations have
been described; including in the noncoding
region.5 With some exceptions, mutations that
result in an altered amino acid sequence cause
CMTX1,6 and most mutations likely cause
loss of function.7 CMTX1 is considered
a dominant disease because most female car-
riers are affected, albeit less so than males.8–13
The presumption is that GJB1 is subjected to
random X-inactivation, so that myelinating
Schwann cells in affected women have mosaic
expression of the mutant and wild-type GJB1;
this has been directly shown in mice.14
The objective of this study was to extend
the phenotypic description of Charcot-
Marie-Tooth disease (CMTX1) and to draw
new genotype-phenotype relationships. We
report on a large cohort of patients
with CMTX1 who were seen at centers affil-
iated with the Inherited Neuropathies
Consortium (INC).
METHODS Standard protocol approvals, registrations,
and patient consents. The NIH-RDCRN and institutional
review boards in the participating centers approved all aspects of
this study. This trial was registered at clinicaltrials.gov (ID
number: NCT01193075). As directed by the institutional review
Figure 1 Amino acid sequence and reported GJB1 mutations
Schematic diagram showing the predicted amino acid sequence and all 420 reported GJB1 mutations (Inherited Neurop-
athies Consortium variant Browser [hihg.med.miami.edu/code/http/cmt/public_html/index.html#/]). Previously unreported
mutations reported are shown in red.
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board, all registry and survey participants received and reviewed
a detailed information letter and provided consent before their
involvement in this research.
Study design, setting, and patient population. Patients
were evaluated at one of the 17 INC centers between 2009 and
2015, and at Wayne State University between 1996 and 2009.
The diagnosis of CMTX1 was established by sequencing GJB1
either in the patients or in a first- or second-degree relative. All
patients with CMTX1 with GJB1 sequencing were included in
this study. History, neurologic examination, and nerve conduc-
tion studies were collected.
Clinical and neurophysiologic data acquisition. The
Charcot-Marie-Tooth disease neuropathy score (CMTNS)
version 1 and/or 2 was used; this is a simple, reliable, and val-
idated standardized assessment tool in adults with CMT.15,16
CMTNS is a composite score based on the history of the
symptoms, neurologic examination, and clinical neurophysiol-
ogy. A CMTNS score of 0–10 is considered mild impairment,
11–20 is considered moderate impairment, and $21 is con-
sidered severe impairment. The Charcot-Marie-Tooth disease
examination score (CMTES) is the sum of the symptoms and
signs portions from the CMTNS without the neurophysiologic
data. CMTES was used for patients who did not undergo
neurophysiologic testing or calculated from CMTNS for pa-
tients with neurophysiologic testing. As in the CMTNS, the
higher the CMTES, the greater the disability. Clinical neuro-
physiologic studies were performed with the temperature
maintained at or above 328C in the hands and feet. Nerve
conduction studies were performed using surface electrodes by
standard techniques.
Statistical analysis. Descriptive statistics were used to analyze
patient characteristics and all available data related to history,
clinical examination, and neurophysiologic testing during the
patient encounter. Our complete-case analyses used missing
data at random assumptions. Two-tailed tests were used when
applicable. A p value of ,0.05 was considered statistically sig-
nificant. The Fisher exact test, Mann-Whitney U test, Spear-
man r, analysis of covariance (ANCOVA), and analysis of
variance were calculated using StatPlus Professional version
5.9.8.5.
RESULTS We evaluated 160 patients with CMTX1
(87 males and 73 females) from 120 different families
who harbored 89 different GJB1 mutations. Of
these 89 mutations, 16 were previously unreported
(p.Trp3Leu, p.Asp66His, p.Ile71Thr, p.Arg75Tyr,
p.Trp77Arg, p.Val84Asp, p.Tyr135CysfsTer11,
p.Arg142Glu, p.Arg142Tyr, p.Arg164Leu, p.Arg164-
Tyr, p.Thr185Ile, p.Ala196Asp, p.Leu212His,
p.Thr269Asn, and p.Asp278_Cys280del). The muta-
tions that are predicted to change the primary
amino acid sequence of Cx32 are shown schemat-
ically in figure 1.
Figure 2 Age, sex, and clinical characteristics of patients with CMTX1 in the cohort
(A) Frequency distribution of age and sex of patients with CMTX1 at the age they were first given a CMTNS in an Inherited
Neuropathies Consortium clinic. (B) Clinical characteristics separated by sex of 160 patients with CMTX1. CMTX1 5 X-
linked form of Charcot-Marie-Tooth disease.
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The 21 most common mutations accounted for
45% of all the identified mutations in families that
were not known to be related (in order; p.Arg15Gln,
p.Glu102Gly, p.Arg22Ter, p.Ala39Val, p.His126-
Tyr, p.Arg164Gln, p.Asp278_Cys280del, p.Ser26-
Leu, p.Ile28Asn, p.Gly159Asp, p.Arg183His,
p.Ser182Cys, p.Ala40Val, p.Val63Ile, p.Cys173Arg,
p.Arg220Ter, c.-17G.A, c.-103C.T, p.Arg142Trp,
c.-17G.A and c.-373G.A). Collectively, the
mutations in the 59 untranslated region were as com-
mon as the most common mutation (p.Arg15Gln)
in our analysis. The frequencies of the mutations
in our cohort are shown graphically in figure e-1 at
Neurology.org.
Figure 2A represents the distribution of patients
according to age and sex at the time they were first
given a CMTNS in an INC clinic. The age of patients
ranged from 5 to 82 years, with a mean of 43 years.
We evaluated 5 members of 1 family, 3 members of 8
families, 2 members of 20 families, and 1 member of
91 families. Of the 91 families with a single evaluated
member, 73 had other affected family members who
we did not see; the remaining 18 patients had no
other known affected family members; we considered
Table 1 Demographic, clinical, and neurophysiologic characteristics classified by sex in 160 patients with X-
linked Charcot-Marie-Tooth disease
Characteristics Males Females p Value
No. of patients 87 73
Age at first visit, y, mean 6 SD 41 6 16 46 6 17 0.02a
Age at onset of walking difficulty, y, mean 6 SD 19 6 14 22 6 13 0.004a
Possible sporadic cases, % (n) 11 (10/87) 11 (8/73)
Delayed walking, >15 mo, % (n) 18 (12/67) 2 (1/64) 0.003b
Dexterity problems, % (n) 74 (64/86) 63 (45/72) 0.2b
Difficulty walking, % (n) 85 (71/84) 64 (46/72) 0.008b
Difficulty balance, % (n) 81 (68/84) 66 (46/70) 0.05b
Foot deformities, % (n) 82 (68/83) 70 (48/69) 0.1b
Orthoses, % (n) 59 (51/86) 60 (43/72) 1b
Walking assistance, % (n) 14 (12/85) 7 (5/73) 1b
Wheelchair-dependent, % (n) 2 (2/84) 1 (1/72) 1b
Foot surgery, % (n) 22 (19/87) 11 (8/73) 1b
Optic nerve atrophy, % (n) 0 (0/76) 0 (0/66)
Hip dysplasia, % (n) 1 (1/82) 0 (0/65)
Hearing loss, % (n) 8 (6/77) 6 (4/71) 1b
Scoliosis, % (n) 10 (8/84) 14 (10/69) 0.5b
Burning feet, % (n) 21 (18/84) 34 (24/71) 0.1b
Arthritic pain, % (n) 34 (28/83) 53 (38/72) 0.03b
CMTES (n) 11 6 5 (80) 8 6 4 (70) 0.001a
CMTES adjusted for age 11 8 0.0004c
CMTNS (n) 15 6 9 (43) 11 6 6 (34) 0.01a
CMTNS adjusted for age 13 14 0.1c
Ulnar CMAP, mV (n); normal 6 mV 2.9 6 2.2 (37) 6.2 6 3.0 (33) 0.000004a
Ulnar motor NCV, m/s (n); normal 50 m/s 35.0 6 5.7 (39) 47.4 6 6.7 (33) 0.000000002a
Ulnar SNAP, mV (n); normal 6 mV 1.6 6 3.4 (27) 7.1 6 9.7 (27) 0.0003a
Median CMAP, mV (n); normal 4 mV 2.3 6 2.4 (28) 5.0 6 2.8 (29) 0.0003a
Median motor NCV, m/s (n); normal 50 m/s 33.7 6 5.0 (25) 41.2 6 7.7 (29) 0.0002a
Radial SNAP, mV (n); normal 15 mV 2.3 6 4.4 (31) 9.0 6 7.3 (29) 0.00004a
Abbreviations: CMAP 5 compound muscle action potential; CMTES 5 Charcot-Marie-Tooth disease examination score;
CMTNS5 Charcot-Marie-Tooth disease neuropathy score; NCV5 nerve conduction velocity; SNAP5 sensory nerve action
potential.
aMann-Whitney U test.
b Fisher exact test.
c Analysis of covariance.
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these to be possible sporadic cases, and they account
for 11% of both male and female patients (figure 2B).
The clinical characteristics of our cohort are
shown in figure 2B. When comparing clinical defi-
cits between women and men, the older age distri-
bution of women should be kept in mind (their
deficits would be expected to worsen with age), in
addition to the consequences of their mosaicism for
the expression of the mutant GJB1 allele (this would
be expected to ameliorate their deficits). Delayed
walking after the age of 15 months was reported
by 18% of males and 2% of females (p 5 0.003),
and 85% of males reported difficulty with walking
compared with 64% of females (p5 0.008). The age
at onset in difficulty walking was younger in men
compared with women (19 and 22 years, respec-
tively; p 5 0.004). Foot deformities and history of
prior foot surgery were not statistically different
between men and women (p 5 0.1 and p 5 1.0,
respectively). Almost all patients were ambulatory,
although more than half required orthoses. Walking
aids were reported in a minority of patients (14% of
males and 7% of females), and few (2% of males and
1% of females) required the use of a wheelchair for
ambulation. Although males were more likely to
report difficulties with balance and dexterity in the
hands, these differences were not statistically signif-
icant. Partial hearing loss was reported in 7% of
patients, but outcomes of formal hearing tests
were not available to us—they harbored c.-17G.A,
p.Phe51Leu, p.Ile71Thr, p.His94Tyr, p.Glu102Gly,
p.His126Tyr, p.Arg142Trp, p.Arg164Gln, p.Cys179-
Tyr, and p.Thr191Phe193Ter mutations. One male
patient (p.Leu165Pro mutation) was noted to have hip
dysplasia. Optic nerve atrophy was not noted in any
patient by routine funduscopic examination. Scoliosis
was reported or noted in 10% of male patients and
14% of female patients (p5 0.5; p.Leu9Trp, p.Val13-
Met, p.Arg22Ter, p.Trp24Cys, p.Ala40Val, p.Ser42fs,
p.Thr55Arg, p.Arg75Tyr, p.Val91Gly, p.His94Tyr,
p.His126Tyr, p.Arg142Tyr, p.Arg142Trp, p.Cy-
s173Arg, p.Cys179Tyr, p.Arg264Cys, p.Thr269Asn,
and p.Ter284Ser mutations). Female patients
were more likely than males to report arthritic pain
that was present most of the time (p 5 0.03).
Female patients were also more likely than
males to report paresthesias with burning features,
34% and 21%, respectively, although this
difference was not statistically significant (table 1
and table e-1).
At their initial visit, males with CMTX1 were
more affected clinically as identified through the
Figure 3 CMT examination score and CMT neuropathy score in male patients with CMTX1
(A) CMTES and CMTNS in male patients with CMTX1 grouped by age. The CMTES is based on history and neurologic exam-
ination; the CMTNS adds neurophysiology. Both CMTES and CMTNS increase with age in male patients with CMTX1 (p ,
0.0005 for both CMTES and CMTNS, analysis of variance). (B) CMTES and CMTNS in female patients with CMTX1 grouped
by age. There is an increase in CMTES (but not CMTNS) after the second decade (p, 0.03, analysis of variance). CMTES 5
Charcot-Marie-Tooth disease examination score; CMTNS 5 Charcot-Marie-Tooth disease neuropathy score; CMTX1 5
X-linked form of Charcot-Marie-Tooth disease.
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CMTES (mean score 5 11) compared with the
CMTES reported for females with CMTX1 (mean
score 5 8, p 5 0.001). Adjusting for age improved
the statistical power without affecting the difference
in mean CMTES scores between men and women.
The combined clinical and neurophysiologic assess-
ments, the CMTNS, showed a similar trend, in
which males were more severely affected than females
(15 and 11, respectively, p 5 0.01). Correcting for
the age difference between men and women abolished
the statistical difference in CMTNS (table 1).
We observed a strong correlation between disabil-
ity and age when male patients were stratified into
groups by age in decades (figure 3A). Increasing age
was strongly associated with increasing CMTES and
CMTNS scores in men, indicating increased disabil-
ity in male patients with CMTX1 (p , 0.0001) (fig-
ure e-2). An analysis of CMTES and CMTNS scores
of female patients stratified into groups by age
showed a change in CMTES, but not CMTNS, for
females with CMTX1 (p, 0.03). There was a signif-
icant increase in CMTES before the third decade of
life in females that did not change thereafter in a sta-
tistically meaningful manner (figure 3B). Contrary to
men with CMTX1, there was no correlation between
advancing age throughout life (as opposed to when
stratified by age group) and CMTES or CMTNS in
females (figure e-2).
In men, the median compound muscle action
potential (CMAP) was reduced compared with women
(2.5 6 2.4 vs 4.9 6 2.9 mV; p 5 0.001), and we
observed a declining correlation with age in men (p 5
0.01, r 5 20.5) but not in women (figure 4A).
The ulnar CMAP was also smaller in men than in
women (3.6 6 2.6 vs 6.2 6 3.0; p 5 0.0004), and
we observed a declining correlation with age in
Figure 4 Nerve conduction studies in male and female patients with CMTX1 according to age
(A) Ulnar and median nerve CMAPs in males and females with CMTX1 by age. The data from individual patients are repre-
sented as single points. There is a correlation between the ulnar and median CMAP with age in males (p 5 0.02, Spearman
r520.4, and p5 0.002, Spearman r520.6, respectively) and ulnar CMAP with age in females (p5 0.002, Spearman r5
20.6). A correlation is not observed between median CMAP with age in females (p5 0.3, Spearman r520.2). (B) Ulnar and
median motor NCVs in males and females with CMTX1 by age. The data from individual patients are represented as single
points. Nerves that did not have a recordable response were excluded. A correlation is not observed between ulnar and
median motor NCVs in males with age (p5 0.8 and 0.2, Spearman r5 0.04 and 0.30, respectively). A correlation is also not
observed between ulnar and median motor NCVs in females with age (p 5 0.7 and 0.4, Spearman r 5 0.06 and 0.10,
respectively). (C) Amplitude of the ulnar and radial SNAPs in males and females with CMTX1 by age. The data from individual
patients are represented as single points. There is a correlation between the radial sensory SNAPs with age in males (p 5
0.01, Spearman r 5 20.4). A correlation is not observed between ulnar sensory SNAPs with age in males (p 5 0.6,
Spearman r 5 20.1). A correlation is also not observed between ulnar and radial SNAPs with age in females (p 5 0.8
and 0.9, Spearman r5 0.04 and 0.01, respectively). CMAP5 compoundmuscle action potential; CMTX15 X-linked form of
Charcot-Marie-Tooth disease; MNCV 5 motor nerve conduction velocity; SNAP 5 sensory nerve action potential.
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women (p 5 0.04, r 5 20.36) but not in men
(figure 4A). In accord, we found that the ulnar motor
nerve conduction velocity (NCV) was slower in male
patients than in female patients (35.4 6 5.8 vs 47.4
6 6.7 m/s; p , 0.0005). Men also had a slower
median motor NCV (33.7 6 5.0 vs 41.2 6 7.7;
p 5 0.004). The median and ulnar motor NCVs
did not slow considerably with age in either males
or females (figure 4B). The amplitudes of the ulnar
(1.7 6 3.5 vs 7.1 6 9.7; p 5 0.0007) and radial
sensory nerve action potentials (SNAPs) (3.5 6 4.4
vs 9.36 7.1; p5 0.0004) were lower in men than in
women (figure 4C). These neurophysiologic assess-
ments for men and women are represented in table 1.
We also analyzed missense mutations in 9 do-
mains of Cx32—the 4 transmembrane domains, 2
extracellular loops, a cytoplasmic loop, and cytoplas-
mic N- and C-termini, in relation to age-adjusted
CMTES in male patients to assess for phenotypic
severity. Although missense mutations in the trans-
membrane domains and the 2 extracellular loops were
associated with higher disease burden compared with
mutations in the cytoplasmic and terminal domains
of the protein, the differences were not statistically
significant in ANCOVA with age used as a covariant
(figure e-3). A similar ANCOVA using all mutations
did not identify a specific mutation causing a milder
or more severe phenotype in males or females.
DISCUSSION The 160 patients with CMTX1
enrolled in the INC are the largest reported cohort
of patients with genetically confirmed CMTX1. We
found 89 different GJB1mutations, including 18 that
have not been previously described. As shown in fig-
ure 1, these 89 mutations span all the domains of
Cx32, so their associated phenotypes should be rep-
resentative of people with CMTX1. We did not iden-
tify specific mutations that resulted in a milder or
more severe phenotype in males or females, consistent
with a previous report that men with CMTX1 have
a similar phenotype regardless of the mutation.7
Although missense mutations in some domains of
Cx32 (i.e., transmembrane domains and extracellular
loops) were associated with higher CMTES and more
severe disease phenotype in males, the differences
were not statistically significant, possibly because of
the small sample size (61 missense mutations in total)
and the weak age covariate that could not compensate
for the loss of the error degree of freedom.
As previously reported,7,14 men were affected more
than women in terms of their age at onset and severity
at any given age. The age at onset of walking difficul-
ties was significantly earlier in men than in women
(mean age of 19 and 22, respectively), and men pre-
sented for evaluation at a younger age (mean age 41)
compared with women (mean age 46). Men were also
more likely than women to complain of difficulties
with walking (85% and 64%, respectively). Men were
more likely than women to report delayed walking
after the age of 15 months; although a majority re-
ported walking before the age of 15 months (82%).
Almost all women in our cohort reported walking
before the age of 15 months in comparison (98%).
In considering these differences between the sexes,
there is a potential of recall bias between men and
women in terms of their reporting. Women were
more likely than men to have arthritic pain; this
was reported in about half of the female patients.
The increased risk of arthritic pain in women is con-
sistent with the extensive literature of increased risk of
clinical pain and increased sensitivity to chronic pain
in women compared with men.17 The specific etio-
logic basis underlying the sex differences related to
pain remains elusive.
On the other hand, some phenotypic features of
the disease were indistinguishable between men and
women. For example, difficulties with hand dexterity
and balance, the need for orthoses, scoliosis, and par-
esthesias in the feet were indistinguishable in their fre-
quency in men and women. There were also no
statistical differences between the sexes in terms of
their need for walking aids, or foot deformities and
surgeries, or wheelchair dependence (which was rare
in both sexes; 2% of males and 1% of females).
Consistent with what is known in CMTX1,7 male
patients in our cohort were more affected both clin-
ically and neurophysiologically than females. The
majority of patients had a moderate level of impair-
ment on the CMTNS score on presentation (mean
score 13). Male patients had higher CMTES and
CMTNS scores (mean CMTNS score 15) compared
with females (mean CMTNS score 11) indicating
a higher disease burden (table 1). The difference in
mean CMTNS between the sexes was more sensitive
to statistical correction for age given the smaller sam-
ple size and less robust initial statistical significance
(table 1). The absence of statistical difference in
CMTNS after adjusting for age should not to be
interpreted as evidence of comparable disease burden
between the sexes. The disease burden, as quantified
by CMTES and CMTNS, increased with age in men
with CMTX1 in contrast to women, in whom the
disease burden remained static after the third decade
of life. This static disease burden in females might be
due to the fact that the rate of disease progression is
below clinical detection after the third decade.
Increasing disability with age in male patients with
CMTX1 has been recognized in the past.7 We
observed a difference in disease burden in women as
measured by CMTES before the third decade when
women were stratified by the age group (figure 3B).
These data suggest that although men are affected at
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an earlier age and are more severely affected than
women, the disease presents early in the life of women
and particularly before the third decade. The age at
onset of walking difficulties in women in our cohort
(mean of 22 years) supports this interpretation. We
state this with caution, however, given the inherent
limitations of extending cross-sectional analysis in
predicting disease progression over a lifetime, and
the possibility that the less affected woman did not
participate in our study.
NCVs have been traditionally used to separate
demyelinating and axonal forms of CMT. CMTX1
has been neurophysiologically characterized as having
“intermediate” slowing—typically 30–40 m/s in
affected males and 30–50 m/s in affected fe-
males.7,10,18 Compared with females with CMTX1,
males had reduced mean ulnar and median CMAPs
and NCVs as well as SNAP amplitudes (table 1). We
found a decreasing correlation of the median and
ulnar nerve CMAP with age in males, whereas there
was a decreasing correlation of ulnar nerve CMAP
with age in females (figure 4A). Although we did
not find statistical correlations between age and
median nerve CMAPs in females in our cohort, this
should not be interpreted as sparing of the median
nerve in females. NCVs were insensitive to advancing
age in our study in both sexes. The faster conduction
velocity in women likely owes to the lesser degree of
demyelination and remyelination in their nerves, the
result of Schwann cells that express the wild-type
GJB1 gene. We also found a decreasing correlation
of the radial nerve SNAP amplitudes with age in
males (figure 4C). We did not find correlations
between age and ulnar SNAPs in men and SNAP
amplitudes in women. The decreased correlations in
CMAP and SNAP amplitudes likely reflect the loss
of large myelinated, motor and sensory axons,
respectively.
Although no pharmacologic interventions exist for
CMTX1, supportive care in the form of gait stabiliza-
tion, addressing foot drop, and treating neuropathic
and mechanical pain are the mainstays of current
therapy. Although men have higher disease burden
in general, our data support the notion that women
are equally likely to report difficulties with balance
and problems with hand dexterity. Early recognition
of these clinical features might therefore be important
in the management of female patients with CMTX1.
Recognition of hand dexterity symptoms in CMTX1
and directing patients to appropriate therapies (e.g.,
occupational therapy) is therefore of paramount
importance.19 Although females have less overall dis-
ease burden compared with males as is evident
through CMTNS or CMTES, they are more likely
to have arthritic type pain requiring symptomatic
therapy. Women with CMTX1 will also likely require
the same attention to orthotic therapy as their male
counterparts based on the data from this cohort.
With the advent of high-throughput screening for
drug candidates in CMT,20 preclinical evidence of
benefit in immune modulation,21 and a successful
gene replacement therapy in a mouse model of
CMTX1,22 one anticipates therapeutic clinical trials
in CMTX1. This effort will benefit from detailed
disease natural history studies, sensitive and robust
outcome measures, and an appropriate patient selec-
tion strategy. In the absence of phenotypic correlation
with specific GJB1 mutations, one envisages that
patient selection will consider the age and sex as the
key considerations. Based on our data, investigating
males makes sense: they are clearly affected earlier in
life, have more severe disease burden at any given age,
and their disability progresses with age, whereas phe-
notypic disease expression in females is seemingly
unaffected by advancing age after the third decade.
Having longitudinal data on these points will be key.
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